BACKGROUND: Chronic viral hepatitis is a potentially important determinant of health care utilization among persons living with HIV. We describe hospitalization rates and reasons for hospitalization among persons living with HIV stratified by coinfection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV). METHODS: Laboratory, demographic, and hospitalization data were obtained for all patients receiving longitudinal HIV care during 2010 at 9 geographically diverse sites. Hepatitis serostatus was assessed by hepatitis B surface antigen and/or hepatitis C antibody. ICD-9 codes were used to assign hospitalizations into diagnostic categories. Negative binomial regression was used to assess factors associated with all-cause and diagnostic category-specific hospitalizations. RESULTS: A total of 2793 hospitalizations were observed among 12,819 patients. Of these patients, 49.3% had HIV monoinfection, 4.1% HIV/HBV, 15.4% HIV/HCV, 2.5% HIV/HBV/HCV, and 28.7% unknown hepatitis serostatus. Compared with HIV monoinfection, the risk of all-cause hospitalization was increased with HIV/HBV [adjusted incidence rate ratio 1.55 (1.17 to 2.06)], HIV/HCV [1.45 (1.21 to 1.74)], and HIV/HBV/HCV [1.52 (1.04 to 2.22)]. Risk of hospitalization for non-AIDS-defining infection was also higher among patients with HIV/HBV [2.07 (1.38 to 3.11)], HIV/HCV [1.81 (1.36 to 2.40)], and HIV/HBV/HCV [1.96 (1.11 to 3.46)]. HIV/HBV was associated with hospitalization for gastrointestinal/liver disease [2.55 (1.30 to 5.01)]. HIV/HCV was associated with hospitalization for psychiatric illness [1.89 (1.11 to 3.26)]. CONCLUSIONS: HBV and HCV coinfection are associated with increased risk of all-cause hospitalization and hospitalization for non-AIDS-defining infections, as compared with HIV monoinfection. Policy-makers and third-party payers should be aware of the heightened risk of hospitalization associated with coinfection when allocating health care resources and considering models of health care delivery.
BACKGROUND:Chronic viral hepatitis is a potentially important determinant of health care utilization among persons living with HIV. We describe hospitalization rates and reasons for hospitalization among persons living with HIV stratified by coinfection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV). METHODS: Laboratory, demographic, and hospitalization data were obtained for all patients receiving longitudinal HIV care during 2010 at 9 geographically diverse sites. Hepatitis serostatus was assessed by hepatitis B surface antigen and/or hepatitis C antibody. ICD-9 codes were used to assign hospitalizations into diagnostic categories. Negative binomial regression was used to assess factors associated with all-cause and diagnostic category-specific hospitalizations. RESULTS: A total of 2793 hospitalizations were observed among 12,819 patients. Of these patients, 49.3% had HIV monoinfection, 4.1% HIV/HBV, 15.4% HIV/HCV, 2.5% HIV/HBV/HCV, and 28.7% unknown hepatitis serostatus. Compared with HIV monoinfection, the risk of all-cause hospitalization was increased with HIV/HBV [adjusted incidence rate ratio 1.55 (1.17 to 2.06)], HIV/HCV [1.45 (1.21 to 1.74)], and HIV/HBV/HCV [1.52 (1.04 to 2.22)]. Risk of hospitalization for non-AIDS-defining infection was also higher among patients with HIV/HBV [2.07 (1.38 to 3.11)], HIV/HCV [1.81 (1.36 to 2.40)], and HIV/HBV/HCV [1.96 (1.11 to 3.46)]. HIV/HBV was associated with hospitalization for gastrointestinal/liver disease [2.55 (1.30 to 5.01)]. HIV/HCV was associated with hospitalization for psychiatric illness [1.89 (1.11 to 3.26)]. CONCLUSIONS:HBV and HCV coinfection are associated with increased risk of all-cause hospitalization and hospitalization for non-AIDS-defining infections, as compared with HIV monoinfection. Policy-makers and third-party payers should be aware of the heightened risk of hospitalization associated with coinfection when allocating health care resources and considering models of health care delivery.
Authors: Rainer Weber; Caroline Sabin; Peter Reiss; Stephane de Wit; Signe W Worm; Matthew Law; Francois Dabis; Antonella D'Arminio Monforte; Eric Fontas; Wafaa El-Sadr; Ole Kirk; Martin Rickenbach; Andrew Phillips; Bruno Ledergerber; Jens Lundgren Journal: Antivir Ther Date: 2010
Authors: C Vellozzi; K Buchacz; R Baker; P R Spradling; J Richardson; A Moorman; E Tedaldi; M Durham; J Ward; J T Brooks Journal: J Viral Hepat Date: 2011-05 Impact factor: 3.728
Authors: Paula Tuma; Jose Medrano; Salvador Resino; Eugenia Vispo; Antonio Madejón; Carlos Sánchez-Piedra; Pablo Rivas; Pablo Labarga; Luz Martín-Carbonero; Pablo Barreiro; Vincent Soriano Journal: Antivir Ther Date: 2010
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: Marcia R Weaver; Christopher J Conover; Rae Jean Proescholdbell; Peter S Arno; Alfonso Ang; Karina K Uldall; Susan L Ettner Journal: J Ment Health Policy Econ Date: 2009-03
Authors: Sara C Keller; Baligh R Yehia; Florence O Momplaisir; Michael G Eberhart; Amanda Share; Kathleen A Brady Journal: AIDS Patient Care STDS Date: 2014-03-21 Impact factor: 5.078
Authors: Christopher T Rentsch; Janet P Tate; Tessa Steel; Adeel A Butt; Cynthia L Gibert; Laurence Huang; Margaret Pisani; Guy W Soo Hoo; Stephen Crystal; Maria C Rodriguez-Barradas; Sheldon T Brown; Matthew S Freiberg; Christopher J Graber; Joon W Kim; David Rimland; Amy C Justice; David A Fiellin; Kristina A Crothers; Kathleen M Akgün Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731
Authors: Kasha P Singh; Megan Crane; Jennifer Audsley; Anchalee Avihingsanon; Joe Sasadeusz; Sharon R Lewin Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Trevor A Crowell; Stephen A Berry; John A Fleishman; Richard W LaRue; Philip T Korthuis; Ank E Nijhawan; Richard D Moore; Kelly A Gebo Journal: J Acquir Immune Defic Syndr Date: 2015-04-01 Impact factor: 3.731
Authors: Olusegun A Adeyemi; Andrew Mitchell; Ashley Shutt; Trevor A Crowell; Nicaise Ndembi; Afoke Kokogho; Habib O Ramadhani; Merlin L Robb; Stefan D Baral; Julie A Ake; Manhattan E Charurat; Sheila Peel; Rebecca G Nowak Journal: BMC Infect Dis Date: 2021-07-06 Impact factor: 3.090